Advice
Following a full submission
mecasermin (Increlex) is accepted for use within NHS Scotland for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (primary IGFD).
Mecasermin significantly improved mean height velocity, mean height velocity standard deviation (SD) score and mean cumulative change in height SD score for at least 6 years. Serious adverse effects including hypoglycaemia and tonsillar hypertrophy are common and long-term safety data are lacking.
Download detailed advice93KB (PDF)
Medicine details
- Medicine name:
- mecasermin (Increlex)
- SMC ID:
- 563/09
- Indication:
- Growth failure in children and adolescents with severe primary insulin-like growth factor-I deficiency (SPIGFD).
- Pharmaceutical company
- Ipsen Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 September 2009